Moxifloxacin

Drug

Drug Profile

Moxifloxacin is a fluoroquinolone antibacterial agent used for specific susceptible bacterial infections. Labeling contains boxed warnings for disabling adverse reactions and recommends reserving use for situations where benefits outweigh risks or where no alternatives exist for some uncomplicated infections. It is a human prescription antibacterial drug.

Drug Class
Fluoroquinolone antibacterial
Approval Status
Marketed human prescription antibacterial drug
Brand Names
  • \Moxifloxacin Tablets\
Indications
  • \Treatment of designated susceptible bacterial infections in adults\

Related News

Related Clinical Trials

NCT ID Title Status Phase
NCT07760246

A Study in Healthy People to Measure How Different Doses of Verducatib Affect the Heart

NOT_YET_RECRUITING PHASE1
NCT07595042

A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)

NOT_YET_RECRUITING PHASE2
NCT07513207

A Study in Healthy People to Test How Vicadrostat Affects the Heart

ACTIVE_NOT_RECRUITING PHASE1
NCT07422298

A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants

COMPLETED PHASE1
NCT07305831

A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)

COMPLETED PHASE1
NCT07272629

A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.

COMPLETED PHASE1
NCT07014735

Effect of Hyperglycaemia and Moxifloxacin on QTc Interval in T2DM

TERMINATED NA
NCT06441006

Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis

RECRUITING PHASE2/PHASE3
NCT06253715

Shortened Regimen for Drug-susceptible TB in Children

RECRUITING PHASE3
NCT05893862

A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)

COMPLETED PHASE1